Cargando…

Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C

About 40% of the Guillain-Barré syndrome (GBS) cases are associated with prodromal infections; occasionally, it has been associated to chronic hepatitis C or its reactivation. A 38-year-old man came to our attention after transaminase elevation occurred during recovery from GBS. All the possible cau...

Descripción completa

Detalles Bibliográficos
Autores principales: Boccia, Filomena, Florio, Letizia Lucia, Durante-Mangoni, Emanuele, Zampino, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645643/
https://www.ncbi.nlm.nih.gov/pubmed/37646952
http://dx.doi.org/10.1007/s13365-023-01167-7
_version_ 1785147397079302144
author Boccia, Filomena
Florio, Letizia Lucia
Durante-Mangoni, Emanuele
Zampino, Rosa
author_facet Boccia, Filomena
Florio, Letizia Lucia
Durante-Mangoni, Emanuele
Zampino, Rosa
author_sort Boccia, Filomena
collection PubMed
description About 40% of the Guillain-Barré syndrome (GBS) cases are associated with prodromal infections; occasionally, it has been associated to chronic hepatitis C or its reactivation. A 38-year-old man came to our attention after transaminase elevation occurred during recovery from GBS. All the possible causes of acute hepatitis were excluded except for the positivity of HCVRNA, and a diagnosis of new onset hepatitis C was made. Recalling patient history, we observed that (i) anti-HCV antibodies were negative and liver enzymes were normal 7 weeks before GBS onset; (ii) in the early stages of ICU admission, liver enzymes started to rise, but the elevation remained mild under steroid treatment; (iii) serum aminotransferase peak occurred 11 weeks after GBS onset; and (iv) HCV RNA was already significantly high when anti-HCV antibodies became positive, consistent with an acute hepatitis. Furthermore, anti-HCV seroconversion was likely delayed or blurred by steroids and immunoglobulin infusions. The interval of time between GBS onset and transaminase elevation compared with the patient clinical history allows us to establish a cause-effect relationship between the two diseases. All patients with GBS should be tested for hepatitis C, or its reactivation if already present, and followed up for an early diagnosis and treatment.
format Online
Article
Text
id pubmed-10645643
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106456432023-11-14 Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C Boccia, Filomena Florio, Letizia Lucia Durante-Mangoni, Emanuele Zampino, Rosa J Neurovirol Case Report About 40% of the Guillain-Barré syndrome (GBS) cases are associated with prodromal infections; occasionally, it has been associated to chronic hepatitis C or its reactivation. A 38-year-old man came to our attention after transaminase elevation occurred during recovery from GBS. All the possible causes of acute hepatitis were excluded except for the positivity of HCVRNA, and a diagnosis of new onset hepatitis C was made. Recalling patient history, we observed that (i) anti-HCV antibodies were negative and liver enzymes were normal 7 weeks before GBS onset; (ii) in the early stages of ICU admission, liver enzymes started to rise, but the elevation remained mild under steroid treatment; (iii) serum aminotransferase peak occurred 11 weeks after GBS onset; and (iv) HCV RNA was already significantly high when anti-HCV antibodies became positive, consistent with an acute hepatitis. Furthermore, anti-HCV seroconversion was likely delayed or blurred by steroids and immunoglobulin infusions. The interval of time between GBS onset and transaminase elevation compared with the patient clinical history allows us to establish a cause-effect relationship between the two diseases. All patients with GBS should be tested for hepatitis C, or its reactivation if already present, and followed up for an early diagnosis and treatment. Springer International Publishing 2023-08-30 2023 /pmc/articles/PMC10645643/ /pubmed/37646952 http://dx.doi.org/10.1007/s13365-023-01167-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Case Report
Boccia, Filomena
Florio, Letizia Lucia
Durante-Mangoni, Emanuele
Zampino, Rosa
Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
title Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
title_full Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
title_fullStr Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
title_full_unstemmed Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
title_short Guillain-Barré syndrome as clinical presentation of a recently acquired hepatitis C
title_sort guillain-barré syndrome as clinical presentation of a recently acquired hepatitis c
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645643/
https://www.ncbi.nlm.nih.gov/pubmed/37646952
http://dx.doi.org/10.1007/s13365-023-01167-7
work_keys_str_mv AT bocciafilomena guillainbarresyndromeasclinicalpresentationofarecentlyacquiredhepatitisc
AT florioletizialucia guillainbarresyndromeasclinicalpresentationofarecentlyacquiredhepatitisc
AT durantemangoniemanuele guillainbarresyndromeasclinicalpresentationofarecentlyacquiredhepatitisc
AT zampinorosa guillainbarresyndromeasclinicalpresentationofarecentlyacquiredhepatitisc